Latest filing published 28 Jul 2025 for Verve Therapeutics, Inc..
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Sekar Kathiresan: trading record in brief
Sekar Kathiresan, listed as chief executive, appears in our data through filings on Verve Therapeutics, Inc. shares, published by SEC (Form 4). In total, 35 filings cover trades dated from 21 June 2021 to 25 July 2025.
Market trades split into 1 purchase (€40k) and 16 sales (€10.4M). Netting one side against the other leaves €10.4M of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 11 option exercises. So far in 2025, the count stands at no purchases and 1 sale.
The latest filing, published on 28 July 2025, reports a transaction in Verve Therapeutics, Inc. The clock since the last published purchase (21 June 2021) now reads 1,967 days. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Sekar Kathiresan
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 348,431 sharesCommon StockSEC:0000950170-25-099260:0
- 33,000 sharesCommon StockSEC:0000950170-25-050563:0
- 30,000 shares0Common StockSEC:0000950170-24-133290:0
- 30,000 shares@ US$2.8710.1% of flowCommon StockSEC:0000950170-24-080012:0
- 50,000 shares@ US$1.398.9% of flowCommon StockSEC:0001209191-22-052799:0
- 50,000 shares@ US$1.398.5% of flowCommon StockSEC:0001209191-22-045447:0
- 50,000 shares@ US$1.398.6% of flowCommon StockSEC:0001209191-22-042871:0
- 160,000 shares0Common StockSEC:0001209191-22-042265:0
- 69,674 shares@ US$2.8728.6% of flowCommon StockSEC:0000899243-22-011767:0
- 1,870 shares@ US$1.390.4% of flowCommon StockSEC:0000899243-22-001203:0
- 42,000 shares@ US$1.398.2% of flowCommon StockSEC:0000899243-21-050032:0
- 57,000 shares@ US$1.3911.1% of flowCommon StockSEC:0000899243-21-049812:0
- 2,500 shares@ US$19.006.3% of flowCommon StockSEC:0000899243-21-025070:0Canonical exit: 19 Sept 2021 (T+90)
13 of 13 declarations
